Trial record 1 of 1 for:    NCT01191086
Previous Study | Return to List | Next Study

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Upsher-Smith Laboratories
ClinicalTrials.gov Identifier:
NCT01191086
First received: August 26, 2010
Last updated: May 15, 2014
Last verified: May 2014
  Purpose

The purpose of this study is to examine the safety of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.


Condition Intervention Phase
Epilepsy
Drug: USL255
Phase 3

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures Who Had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study

Resource links provided by NLM:


Further study details as provided by Upsher-Smith Laboratories:

Primary Outcome Measures:
  • Evaluate the safety of USL255 through the collection of adverse events and clinical laboratory evaluations

Secondary Outcome Measures:
  • Summary of weekly seizure frequency during the open-label treatment study.

Estimated Enrollment: 172
Study Start Date: October 2010
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: USL255 Open Label Study Drug: USL255

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have completed the maintenance period of the P09-004 study.
  • Continue to be treated with a stable dose of 1 to a maximum of 3 approved concomitant AEDs.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01191086

  Hide Study Locations
Locations
United States, Arizona
Phoenix, Arizona, United States
United States, California
Ventura, California, United States
United States, Florida
Gainsville, Florida, United States
Gulf Breeze, Florida, United States
Jacksonville, Florida, United States
Port Charlotte, Florida, United States
United States, Kentucky
Lexington, Kentucky, United States
United States, Maryland
Waldorf, Maryland, United States
United States, Missouri
Chesterfield, Missouri, United States
St Louis, Missouri, United States
United States, New Jersey
Somerset, New Jersey, United States
United States, North Carolina
Charlotte, North Carolina, United States
United States, Ohio
Toledo, Ohio, United States
United States, Texas
Dallas, Texas, United States
Temple, Texas, United States
United States, Wisconsin
Milwaukee, Wisconsin, United States
Argentina
Buenos Aires, Argentina
Cordoba, Argentina
Guaymallen, Argentina
Salta, Argentina
Australia
Bedford Park, Australia
Clayton, Australia
Fitzory, Australia
Heidelberg West, Australia
Parkville, Australia
Randwick, Australia
Woodville, Australia
Belgium
Brugge, Belgium
Duffel, Belgium
Leuven, Belgium
Canada
Greenfield Park, Canada
Toronto, Canada
Chile
Santiago, Chile
Valdivia, Chile
Germany
Bonn, Germany
Munich, Germany
Greece
Athens, Greece
Thessaloniki, Greece
India
Bangalore, India
Dehradun, India
Hyderabad, India
Mangalore, India
Mumbai, India
New Delhi, India
Israel
Ashkelon, Israel
Holon, Israel
Nahariya, Israel
Petach Tikva, Israel
Ramat Gan, Israel
New Zealand
Auckland, New Zealand
Poland
Gdansk, Poland
Katowice, Poland
Krakow, Poland
Lodz, Poland
Lublin, Poland
Warszawa, Poland
Russian Federation
Kazan, Russian Federation
Moscow, Russian Federation
Samara, Russian Federation
St Petersburg, Russian Federation
Tyumen, Russian Federation
Yaroslavi, Russian Federation
South Africa
Cape Town, South Africa
Spain
Badalona, Spain
Baracaldo, Spain
Granada, Spain
Madrid, Spain
Valencia, Spain
Sponsors and Collaborators
Upsher-Smith Laboratories
  More Information

No publications provided

Responsible Party: Upsher-Smith Laboratories
ClinicalTrials.gov Identifier: NCT01191086     History of Changes
Other Study ID Numbers: P09-005
Study First Received: August 26, 2010
Last Updated: May 15, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Upsher-Smith Laboratories:
Epilepsy
partial onset seizure
adjunctive therapy

Additional relevant MeSH terms:
Seizures
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on September 18, 2014